Double-blind Placebo: Clinical Trials

7 trials of Double-blind Placebo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 5 Phase 3, 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5
Phase 22Completed 2
Phase 11Terminated 1

Follow Double-blind Placebo: new trials by email Literature Review of Double-blind Placebo trials Research Report on Double-blind Placebo

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Open-label Pitolisant, Double-blind Placebo, Double-blind Pitolisant - Idiopathic Hypersomnia
Phase 3CompletedHarmony Biosciences Management, Inc.2142022-05-252026-09-25
A Trial of NT-I7 in COVID-19 (SPESELPIS)
Double-Blind NT-I7, Double-Blind Placebo - COVID-19
Phase 1TerminatedNeoImmuneTech72020-11-272023-07-14
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307 - Moderate to Severe Ulcerative Colitis
Phase 2CompletedConnect Biopharm LLC1452019-02-272024-05-06
A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
Double-Blind Placebo, Double-Blind Rituximab - Scleroderma, Systemic, Skin Sclerosis
Phase 2 / Phase 3CompletedTokyo University562017-12-042020-02-18
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
open-label rifaximin, double-blind placebo, double-blind rifaximin - Irritable Bowel Syndrome With Diarrhea
Phase 3CompletedBausch Health Americas, Inc.25832012-02-012017-12-12
A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis
Double-blind adalimumab, Double-blind Placebo, Open-label Adalimumab - Rheumatoid Arthritis
Phase 3CompletedAbbott3342009-03-012012-08-07
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept - Rheumatoid Arthritis
Phase 3CompletedBristol-Myers Squibb17952002-12-012011-11-24

Conditions studied

Arthritis, Rheumatoid (2)  ·  Autoimmune Diseases (1)  ·  COVID-19 (1)  ·  Collagen Diseases (1)  ·  Diarrhea (1)  ·  Idiopathic Hypersomnia (1)  ·  Pulmonary Fibrosis (1)  ·  Scleroderma, Systemic (1)  ·  Sleepiness (1)

Sponsors

Abbott (1)  ·  Bausch Health Americas, Inc. (1)  ·  Bristol-Myers Squibb (1)  ·  Connect Biopharm LLC (1)  ·  Harmony Biosciences Management, Inc. (1)  ·  NeoImmuneTech (1)  ·  Tokyo University (1)

Countries

United States (5)  ·  Japan (2)  ·  China (1)  ·  Germany (1)  ·  Pakistan (1)  ·  Ukraine (1)  ·  United Kingdom (1)

Top investigators

Ayumi Yoshizaki, MD, PhD (1)  ·  Enoch Bortey, PhD (1)  ·  Hiroshi Ukai, BS (1)  ·  Suzhou Connect (1)

Results publications

PMID 24441150, PMID 27338778, PMID 27528177, PMID 27795384, PMID 28589238, PMID 28932270, PMID 29329602, PMID 29708822, PMID 35136981, PMID 36922331, PMID 38279402, PMID 38294008